Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Lung Cancer Oncologists (US)

Articles with lock require a subscription to GLG News | Request a free trial
March 20, 2008
Lung cancer vaccination: a kinder, gentler (sic) therapy?? We will see..
Analysis of: Phase II Randomized Controlled Trial of an Epidermal Growth Factor Vaccine in Advanced Non–Small-Cell Lung Cancer | jco.ascopubs.org
Author: GLG Expert Contributor
Vaccination with EGF was used in a maintenance situation after initial chemo. No only did it produce EGF antibodies BUT the antibody response was correlated with survival!!
March 20, 2008
Revlimid in non-myeloma malignancies? A review article? It's time is coming!
Analysis of: Lenalidomide for the Treatment of B-Cell Malignancies | jco.ascopubs.org
Author: GLG Expert Contributor
Revlimid has significant activity in non Hodgkin's lymphomas (NHL)as well as chronic lymphatic leukemia (CLL) although why is somewhat unclear.
March 19, 2008
Avastin (Genentech) a double edged sword?
Analysis of: Doctors See How Cancer Drug Can Damage Kidneys | www.washingtonpost.com
Author: GLG Expert Contributor
Avastin, an antiangiogenic agent used in cancer and other disorders, may have more side effects than originally recognized including proteinuria as well as kidney damage.
March 17, 2008
Genzyme's Cerezyme: When is enough enough
Analysis of: Cutting Dosage of Costly Drug Spurs a Debate | www.nytimes.com
Author: GLG Expert Contributor
Pharma recommends more drug than may actually be needed. This does not apply just to Cerezyme, but the Epo products (Amgen & J&J), Avastin (Genentech.)
March 17, 2008
Fraud: Inevitable no matter who is in charge
Analysis of: 5 Guilty of Fraud in Health Care Finance | www.nytimes.com
Author: GLG Expert Contributor
Prison terms to be handed out for fraud by a health care financing firm. Go figure?
March 14, 2008
The FDA givith (Amgen's Nplate) and takith away (Amgen's Aranesp)
Analysis of: Platelet Treatment Wins FDA Panel's Support | online.wsj.com
Author: GLG Expert Contributor
This is an agent, approved for use with restrictions, in ITP.
March 14, 2008
FDA & Epo: Not as bad as expected!
Analysis of: FDA Panel Backs Anemia Drugs For Cancer Patients, but With Limits | online.wsj.com
Author: GLG Expert Contributor
Epo products (Aranesp, Procrit, Epogen) from Amgen and J & J will be restricted to some degree with control of hemoglobin levels, NO use in curable malignancies ..." the panel voted 11 to 2 in recommending that the drugs not be used in cancer patients who are likely to be cured from their...
March 11, 2008
A third world country balking at the cost of high priced cancer drugs their citizens can't afford? Go figure....
Analysis of: Thai Ministry to Recommend Ignoring Patents on Cancer Drugs | online.wsj.com
Author: GLG Expert Contributor
Manufacturers include Roche Holding AG and Novartis AG of Switzerland and Sanofi-Aventis. Generic versions of the antineoplastic agents will be made available and the patents obviously ignored.
March 10, 2008
Amgen and J & J: FDA adding insult to injury #5
Analysis of: FDA Adds More Black-Box Warnings To Anemia Drugs From Amgen, J&J | online.wsj.com
Author: GLG Expert Contributor
The FDA is now warning of increased death & tumor growth in breast and cervical cancer patients.
March 10, 2008
Wouldn't you want 5 1/2 more months if you had metastatic breast cancer?
Analysis of: The High Cost of a Cancer Drug | www.nytimes.com
Author: GLG Expert Contributor
This editorial is questioning the use of this expensive agent in patients with metastatic breast cancer when it only increases time to progression 5.5 months.

Previous Page : 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 Next131 to 140 of 450

More GLG News in
Healthcare

Most Popular:
Source Article | Expert Analyses
 

GLG News: What Experts Think Is Important





Analytics


Generated at 2008-12-02T09:45:16.440